Form 4: Monopar Therapeutics CFO Reports Stock Transaction
Insider Transaction (Form 4)
Quan Anh Vu, Chief Financial Officer of Monopar Therapeutics, reported multiple transactions in common stock on September 30, 2026.
Summary
- Option exercise/conversion: acquired 614 Common Stock on September 30, 2026; holds 2,835 after (Direct).
- Tax/exercise-price withholding: disposed of 180 Common Stock at $79.67 ($14,341) on September 30, 2026; holds 2,655 after (Direct).
- Option exercise/conversion: disposed of 614 Restricted Stock Unit on September 30, 2026; holds 7,984 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Quan Anh Vu — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Option exercise/conversion | Common Stock | 614 | — | — | 2,835 |
| 2026-09-30 | Tax/exercise-price withholding | Common Stock | 180 | $80 | $14.3K | 2,655 |
| 2026-09-30 | Option exercise/conversion | Restricted Stock Unit | 614 | — | — | 7,984 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Option exercise/conversion (614 shares) |
| 2026-09-30 | Tax/exercise-price withholding (180 shares) |
| 2026-09-30 | Option exercise/conversion (614 shares) |
Keywords
insider transaction, Form 4, MNPR, Monopar Therapeutics, neutral, Quan Anh Vu
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.